Shares of Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) traded down 1.9% during trading on Wednesday . The company traded as low as $128.10 and last traded at $129.21, with a volume of 471,479 shares traded. The stock had previously closed at $131.73.

A number of analysts have commented on the stock. Cowen and Company reaffirmed a “buy” rating on shares of Alexion Pharmaceuticals in a report on Wednesday, June 8th. Credit Suisse Group AG raised shares of Alexion Pharmaceuticals from a “neutral” rating to an “outperform” rating in a research report on Saturday, July 9th. Zacks Investment Research raised shares of Alexion Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, May 30th. Royal Bank Of Canada assumed coverage on shares of Alexion Pharmaceuticals in a research report on Tuesday, July 12th. They set an “outperform” rating and a $188.00 price target on the stock. Finally, Vetr raised shares of Alexion Pharmaceuticals from a “buy” rating to a “strong-buy” rating and set a $171.50 price target on the stock in a research report on Wednesday, June 8th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, thirteen have assigned a buy rating and two have given a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $182.85.

The company has a market cap of $29.23 billion, a price-to-earnings ratio of 327.54 and a beta of 1.08. The company’s 50-day moving average price is $131.16 and its 200 day moving average price is $135.82.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/alexion-pharmaceuticals-inc-alxn-shares-down-1-9.html

Alexion Pharmaceuticals (NASDAQ:ALXN) last released its quarterly earnings results on Thursday, July 28th. The biopharmaceutical company reported $1.13 earnings per share for the quarter, missing analysts’ consensus estimates of $1.17 by $0.04. Alexion Pharmaceuticals had a net margin of 3.19% and a return on equity of 10.02%. The firm had revenue of $753 million for the quarter, compared to the consensus estimate of $743.18 million. During the same period in the previous year, the business earned $1.44 earnings per share. The firm’s revenue for the quarter was up 18.4% on a year-over-year basis. Equities research analysts forecast that Alexion Pharmaceuticals Inc. will post $4.65 earnings per share for the current year.

In related news, Director Alvin S. Parven sold 15,000 shares of the firm’s stock in a transaction dated Monday, August 22nd. The shares were sold at an average price of $136.53, for a total transaction of $2,047,950.00. Following the completion of the sale, the director now owns 6,373 shares in the company, valued at $870,105.69. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Carsten Thiel sold 3,225 shares of the firm’s stock in a transaction dated Tuesday, September 13th. The stock was sold at an average price of $128.67, for a total transaction of $414,960.75. Following the sale, the executive vice president now owns 40,354 shares of the company’s stock, valued at approximately $5,192,349.18. The disclosure for this sale can be found here. Corporate insiders own 4.41% of the company’s stock.

Hedge funds have recently bought and sold shares of the company. Meeder Asset Management Inc. bought a new stake in Alexion Pharmaceuticals during the first quarter worth about $114,000. NEXT Financial Group Inc increased its stake in Alexion Pharmaceuticals by 66.1% in the second quarter. NEXT Financial Group Inc now owns 1,106 shares of the biopharmaceutical company’s stock worth $129,000 after buying an additional 440 shares during the period. Bellwether Investment Group LLC bought a new stake in Alexion Pharmaceuticals during the second quarter worth about $172,000. Charlemagne Capital Ltd. bought a new stake in Alexion Pharmaceuticals during the second quarter worth about $191,000. Finally, Evercore Wealth Management LLC increased its stake in Alexion Pharmaceuticals by 5.0% in the second quarter. Evercore Wealth Management LLC now owns 1,735 shares of the biopharmaceutical company’s stock worth $203,000 after buying an additional 83 shares during the period. Institutional investors and hedge funds own 96.34% of the company’s stock.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).

5 Day Chart for NASDAQ:ALXN

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.